Literature DB >> 24931922

Can 18F-FDG PET improve the evaluation of suspicious breast lesions on MRI?

Almir G V Bitencourt1, Eduardo N P Lima2, Rubens Chojniak3, Elvira F Marques4, Juliana A Souza5, Wesley P Andrade6, Marcos D Guimarães7.   

Abstract

OBJECTIVE: To evaluate the impact of adding 18F-fluorine-2-deoxy-d-glucose (FDG) positron emission tomography (PET) in the evaluation of suspicious breast lesions on magnetic resonance imaging (MRI).
METHODS: Sixty patients with suspicious breast lesions on MRI were selected to perform a PET-CT in prone position, dedicated to the evaluation of the breasts. The areas with increased 18F-FDG concentration relative to normal parenchyma were considered positive on PET-CT. Fusion of PET and MRI images (PET-MRI) was performed on a dedicated workstation to better locate corresponding lesions, and its findings were compared with histological results.
RESULTS: 76 lesions were evaluated, including 64 mass lesions (84.2%) and 12 non-mass lesions (15.8%). Lesions' mean diameter on MRI was 29.6 ± 19.2 mm (range 6-94 mm). PET-CT showed increased metabolically activity on 57 lesions (75.0%), with mean maximum SUV of 5.7 ± 5.0 (range 0.8-23.1). On histopathology, there were 17 (22.4%) benign and 59 (79.7%) malignant lesions. Considering all lesions, PET-MRI fusion provided 89.8% sensitivity, 76.5% specificity and 86.8% accuracy. Considering only mass lesions higher than 10mm, PET-MRI fusion provided 95.8% sensitivity, 83.3% specificity and 93.3% accuracy.
CONCLUSION: The inclusion of 18F-FDG PET on the evaluation of suspicious breast lesions on MRI helped to differentiate benign from malignant breast lesions, especially for mass lesions with a diameter higher than 10 mm.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Breast cancer; Fluorodeoxyglucose F18; Magnetic resonance imaging; Positron-emission tomography; Prone position

Mesh:

Substances:

Year:  2014        PMID: 24931922     DOI: 10.1016/j.ejrad.2014.05.021

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  6 in total

1.  Clinical utility of 18F-FDG-PET/MR for preoperative breast cancer staging.

Authors:  Diomidis Botsikas; Anastasia Kalovidouri; Minerva Becker; Michele Copercini; Dahila Amal Djema; Alexandre Bodmer; Sindy Monnier; Christoph D Becker; Xavier Montet; Benedicte M A Delattre; Osman Ratib; Valentina Garibotto; Claire Tabouret-Viaud
Journal:  Eur Radiol       Date:  2015-10-17       Impact factor: 5.315

2.  MRI fused with prone FDG PET/CT improves the primary tumour staging of patients with breast cancer.

Authors:  Maria J Garcia-Velloso; Maria J Ribelles; Macarena Rodriguez; Alejandro Fernandez-Montero; Lidia Sancho; Elena Prieto; Marta Santisteban; Natalia Rodriguez-Spiteri; Miguel A Idoate; Fernando Martinez-Regueira; Arlette Elizalde; Luis J Pina
Journal:  Eur Radiol       Date:  2016-12-21       Impact factor: 5.315

3.  Measuring Glucose Uptake in Primary Invasive Breast Cancer Using Simultaneous Time-of-Flight Breast PET/MRI: A Method Comparison Study with Prone PET/CT.

Authors:  Amy M Fowler; Manoj Kumar; Leah Henze Bancroft; Kelley Salem; Jacob M Johnson; Jillian Karow; Scott B Perlman; Tyler J Bradshaw; Samuel A Hurley; Alan B McMillan; Roberta M Strigel
Journal:  Radiol Imaging Cancer       Date:  2021-01-15

Review 4.  Breast PET/MR Imaging.

Authors:  Amy Melsaether; Linda Moy
Journal:  Radiol Clin North Am       Date:  2017-02-01       Impact factor: 2.303

5.  Multiparametric evaluation of breast lesions using PET-MRI: initial results and future perspectives.

Authors:  Almir G V Bitencourt; Eduardo N P Lima; Rubens Chojniak; Elvira F Marques; Juliana A Souza; Wesley P Andrade; Marcos D Guimarães
Journal:  Medicine (Baltimore)       Date:  2014-11       Impact factor: 1.889

6.  Investigation of Added Value of Imaging Performed in a Prone Position to Standard 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Imaging for Staging in Patients with Breast Cancer.

Authors:  Ezgi Başak Erdoğan; Mehmet Aydın
Journal:  Mol Imaging Radionucl Ther       Date:  2022-02-02
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.